HomeCompareBLPH vs PLD

BLPH vs PLD: Dividend Comparison 2026

BLPH yields 158.04% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLPH wins by $26.18M in total portfolio value
10 years
BLPH
BLPH
● Live price
158.04%
Share price
$0.01
Annual div
$0.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.68M
Annual income
$14,560,088.59
Full BLPH calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — BLPH vs PLD

📍 BLPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLPHPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLPH + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLPH pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLPH
Annual income on $10K today (after 15% tax)
$13,433.54/yr
After 10yr DRIP, annual income (after tax)
$12,376,075.30/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, BLPH beats the other by $7,908,104.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLPH + PLD for your $10,000?

BLPH: 50%PLD: 50%
100% PLD50/50100% BLPH
Portfolio after 10yr
$19.59M
Annual income
$9,908,262.39/yr
Blended yield
50.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

BLPH
Analyst Ratings
7
Buy
1
Hold
Consensus: Buy
Altman Z
-77.3
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLPH buys
0
PLD buys
0
No recent congressional trades found for BLPH or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLPHPLD
Forward yield158.04%3.18%
Annual dividend / share$0.02$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$32.68M$6.50M
Annual income after 10y$14,560,088.59$5,256,436.18
Total dividends collected$30.36M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: BLPH vs PLD ($10,000, DRIP)

YearBLPH PortfolioBLPH Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$26,504$15,804.17$11,255$555.24+$15.2KBLPH
2$67,507$39,147.31$13,062$1,018.59+$54.4KBLPH
3$165,418$93,186.16$15,903$1,926.67+$149.5KBLPH
4$390,402$213,404.75$20,839$3,823.32+$369.6KBLPH
5$888,436$470,705.22$30,464$8,166.08+$858.0KBLPH
6$1,951,729$1,001,103.05$52,054$19,457.30+$1.90MBLPH
7$4,143,713$2,055,363.02$109,886$54,188.93+$4.03MBLPH
8$8,512,033$4,078,259.67$304,030$186,451.18+$8.21MBLPH
9$16,937,387$7,829,511.79$1,166,125$840,813.32+$15.77MBLPH
10$32,683,093$14,560,088.59$6,504,190$5,256,436.18+$26.18MBLPH

BLPH vs PLD: Complete Analysis 2026

BLPHStock

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Full BLPH Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this BLPH vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLPH vs SCHDBLPH vs JEPIBLPH vs OBLPH vs KOBLPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.